Bulwark Capital’s Novavax NVAX Stock Holding History

Bulwark Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.75K	Hold	610	–	–	﹤0.01%	97
2026 Q1	$4.96K	Hold	610	–	–	﹤0.01%	93
2025 Q4	$4.1K	Hold	610	–	–	﹤0.01%	90
2025 Q3	$5.29K	Hold	610	–	–	﹤0.01%	94
2025 Q2	$3.84K	Buy	+610	New	+$4.04K	﹤0.01%	88

Other funds holding NVAX

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Bulwark Capital's NVAX Position: Q2 2026 in Review

Bulwark Capital held its Novavax (NVAX) position steady in Q2 2026 at 610 shares worth $5.75K. The position accounts for ﹤0.01% of the portfolio, ranked #97.

Bulwark Capital first reported a position in NVAX in Q2 2025 and has held it in 5 quarters since. 70 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Bulwark Capital held 610 shares of Novavax worth $5.75K as of Q2 2026.
Bulwark Capital left its Novavax share count unchanged in Q2 2026.
Novavax made up ﹤0.01% of Bulwark Capital's portfolio in Q2 2026, its #97 holding.
Bulwark Capital first reported a position in Novavax in Q2 2025 and has held it in 5 quarters since.
70 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Bulwark Capital's 13F filing for Q2 2026, filed 6 Jul 2026.